GSK plc (GSK)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Investors who purchased GSK securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether GSK and certain of its officers and/or directors have violated federal securities laws.
On August 9, 2022, Vir Biotechnology, Inc. (“Vir”), GSK’s development partner for the proposed COVID-19 treatment sotrovimab, issued a press release disclosing that that Vir “and GSK do not plan to file a Biologics License Application for sotrovimab at this time and do not intend to pursue the US-based Phase 3 COMET-STAR prophylaxis trial. Discussions with the FDA remain ongoing regarding the appropriate path forward for sotrovimab in the US.” On this news, GSK’s American Depositary Receipt price fell sharply during intraday trading on August 10, 2022.
If you are aware of any facts relating to this investigation, or purchased GSK shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.